GENetic Education Risk Assessment and TEsting Study

Around 1 in 10 (10%) pancreatic cancer patients carries an inherited change (mutation) in a
gene which can increase the risk of cancer. Relatives of patients with pancreatic cancer are
often unaware that the mutation can be passed down through the family. Having information
about genetic risk can be important to family members. There may be options for early and/or
more frequent screening (to look for cancer or pre-cancer) or early detection
recommendations.

This research is being done to study the impact of different methods of teaching about and
offering genetic testing to family members of pancreatic cancer patients who carry a
mutation.

Study arms:

Individuals will be randomized (like flipping a coin) by family to one of the two study arms
to receive genetic education and elect to undergo genetic testing.

Individuals in Arm 1 (video conference platform plus Color Genomics) will receive genetic
education via a pre-recorded educational video and interactive session with the study team
through an internet-based platform.

Individuals in Arm 2 (Color Genomics Only) will receive genetic education from Color
Genomics, Inc., an online, commercial genetic testing service.

Informed consent:

Participants will be asked to provide informed consent in order to join the study.

Study questionnaires:

Questionnaires will be given at baseline and throughout the duration of the study.
Participants will be asked to complete baseline questionnaires through the online study
database, called REDCap. These questionnaires will ask participants about their medical
history, their experience with pancreatic cancer and other relevant health behaviors.

The follow-up questionnaires will ask about how much participants worried about cancer, how
participants made choices, their knowledge gained and how much families shared genetic test
results (if participants chose to get testing). The study will also ask about participants'
choices to have pancreas exams and other surveillance (long-term screening) procedures, and
their lifestyle choices after receiving the intervention.

Genetic testing:

GENERATE offers genetic testing at no cost to participants in the study. Color Genomics will
provide the genetic testing services for the study. Participants will be directed to create a
personal Color Genomics account that will allow them to enter their personal and family
history information, keep track of their genetic testing kit and receive their genetic test
results. Participants will be mailed an FDA-approved saliva collection kit from Color
Genomics. When participants receive the kit in the mail, they will be able to use the kit's
unique barcode number to activate it and link it to their online account. A video on the
website will show participants how to provide a large enough saliva sample. It will also
contain instructions for how to properly package and mail back the kit to Color Genomics
using a pre-paid shipping package.

Getting test results:

It usually takes about 4-6 weeks to get the results back from this genetic test. Participants
will receive an email letting them know that their results are available for review through
their Color Genomics account or via a phone call with a genetics counselor.

Length of study:

The total participation on this study will last about 18 months, including follow-up.
Participants may be contacted regarding participation in future studies.

Inclusion Criteria:

- Individual who is 18 years or older

- Individual who has signed the informed consent

- Individual who has been informed about:

- A first or second-degree relative with a diagnosis of pancreatic ductal
adenocarcinoma (PDAC) and a germline mutation in APC, ATM, BRCA1, BRCA2, CDKN2A,
EPCAM, MLH1, MSH2, MSH6, PALB2, PMS2, STK11, or TP53, OR

- An unaffected first or second-degree relative with a germline mutation in one of
these genes who is a first or second-degree relative to a PDAC case

- The germline mutation and history of PDAC must both be on the maternal side or
paternal side of the individual's family

- Individual with a valid United States mailing address

- Individual with access to a healthcare provider and is willing to share genetic test
results with that provider/the study team

Exclusion Criteria:

- Individual with a known cancer susceptibility gene

- Individual who has received prior genetic counseling for cancer risk

- Individual who has received a bone marrow transplant, who has had a blood transfusion
within the last 7 days, or who has an active hematologic malignancy (i.e. leukemia or
lymphoma)

- Individual who is unable to sign the informed consent because of mental incompetency
or psychiatric illness

- Individual who is unwilling to complete baseline and follow-up questionnaires

- Individual who has a life expectancy of less than 1 year